The WOVEN trial: Wingspan One-year Vascular Events and Neurologic Outcomes
Michael J Alexander, Alois Zauner, Rishi Gupta, Amer Alshekhlee, Justin F Fraser, Gabor Toth, Curtis Given, Larami Mackenzie, Brian Kott, Ameer E Hassan, Harish Shownkeen, Blaise W Baxter, R Charles Callison, Wengui Yu, Michael J Alexander, Alois Zauner, Rishi Gupta, Amer Alshekhlee, Justin F Fraser, Gabor Toth, Curtis Given, Larami Mackenzie, Brian Kott, Ameer E Hassan, Harish Shownkeen, Blaise W Baxter, R Charles Callison, Wengui Yu
Abstract
Background: Prior studies evaluating the Wingspan stent for treatment of symptomatic intracranial atherosclerotic disease have included patients with a spectrum of both on-label and off-label indications for the stent. The WEAVE trial assessed 152 patients stented with the Wingspan stent strictly by its current on-label indication and found a 2.6% periprocedural stroke and death rate.
Objective: This WOVEN study assesses the 1-year follow-up from this cohort.
Methods: Twelve of the original 24 sites enrolling patients in the WEAVE trial performed follow-up chart review and imaging analysis up to 1 year after stenting. Assessment of delayed stroke and death was made in 129 patients, as well as vascular imaging follow-up to assess for in-stent re-stenosis.
Results: In the 1-year follow-up period, seven patients had a stroke (six minor, one major). Subsequent to the periprocedural period, no deaths were recorded in the cohort. Including the four patients who had periprocedural events in the WEAVE study, there were 11 strokes or deaths of the 129 patients (8.5%) at the 1-year follow-up.
Conclusions: The WOVEN study provides the 1-year follow-up on a cohort of 129 patients who were stented according to the current on-label use. It provides a more homogeneous patient group for analysis than prior studies, and demonstrates a relatively low 8.5% 1-year stroke and death rate in stented patients.
Keywords: atherosclerosis; intervention; stenosis; stent; stroke.
Conflict of interest statement
Competing interests: MJA, AZ, RG, AEH, BWB, RCC and WY are scientific consultants for Stryker Neurovascular. No industry compensation was provided for this research or the production of this manuscript to any of the investigators.
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Source: PubMed